Recruiting

LONGEVITI

Sponsor:

University of Alberta

Code:

NCT05645510

Conditions

Cancer

Tyrosine Kinase Mutation

Breast Cancer

Melanoma

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Conditions

Cancer

Tyrosine Kinase Mutation

Breast Cancer

Melanoma

Multiple Myeloma

Study ID

NCT05645510

Start date

Nov 24, 2022

Status verified date

May, 2026

Completion date

Jun 9, 2026

Anticipated

Primary completion date

Jun 9, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria: taking chronic targeted anti-cancer agents -

Exclusion Criteria:

\-

Study Design

Enrollment

75 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Interview [ Time Frame: 3 months ]

Central Contacts and Locations

Central contacts

Edith Pituskin, PhD

7804328221pituskin@ualberta.ca

Meredith Porter Hogg, MN

lngeviti@ualberta.ca

Locations

Edith Pituskin

Recruiting

Edmonton, Alberta, Canada, T6G 1C9

Contacts

Edith Pituskin, PhD

7804328221pituskin@ualberta.ca

More Information

Sponsor

University of Alberta

Last update posted

May 11, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-05-11.